Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
115 Cards in this Set
- Front
- Back
Autograft
|
a graft transplanted into the same individual from which it came
|
|
Syngeneic Graft
|
a graft transplanted between genetically identical individuals
|
|
Circumstances conducive to formation of immune complexes (3)
|
1. Persistent low grade infection
2. Autoimmunity (antigens always present) 3. Formation at body surfaces |
|
Farmer's Lung Disease
|
Circulating antibodies trigger inflammation and compromise lung function
From repeated exposure to moldy hay |
|
How are immune complexes usually destroyed? (2) Where?
|
Phagocytosis in the liver/spleen
RBC's bind compliment that has been fixed by the complexes, then removed by hepatic macrophages |
|
What happens after complexes deposit in tissues?
|
1. They activate compliment
2. Compliment activation leads to recruitment and activation of inflammatory cells 3. Neutrophils cause tissue injury |
|
What size complexes are most prone to deposition in tissues?
|
Intermediate
|
|
What factors influence the deposition of immune complexes?
|
1. Size - intermediate deposit more readily
2. Clearance rate 3. Charge - + charged complexes bind to - charged components of the glomerular basement membrane 4. Anatomic factors - filtering and tortuous vessels |
|
What causes chronic serum sickness?
|
Multiple injections of antigen or continual exposure to self antigens
|
|
What does chronic serum sickness cause?
|
Formation of smaller complexes that deposit in kidneys, arteries, lung vasculature
|
|
Systemic Lupus Erythematosus
|
small complexes deposited in the blood
antibodies are produced against nuclear antigens such as DNA |
|
Arthus Reaction
|
antigen injected subcutaneously
individual already has antibodies for that antigen complexes form and deposit in the walls of the small arteries at the injection site. = local cutaneous vasculitis with necrosis |
|
Hypersensitivity reactions of the eye
(2) |
1. Peripheral corneal lesions
2. Uveitis |
|
How long does type 4 hypersensitivity reaction take to develop?
|
More than 12 hours
|
|
Two types of delayed type hypersensitivity
|
1. Contact hypersensitivity
2. Tuberculin-type hypersensitivity |
|
What causes blistering in contact hypersensitivity?
|
T cells and macrophages gather around the local vasculature int he dermis.
These cells infiltrate into the epidermis, where they act to eliminate the antigen. |
|
What is the hallmark of a TB-type hypersensitivity?
|
Induration (hardness)
|
|
What causes the hardness in TB-type hypersensitivity?
|
T cells and macrophages gather in the dermis
|
|
Langerhan's Cells
|
specialized APC's in the epidermis that process antigens then migrate to the draining lymphnodes where they present their antigen to the T cells, activating them.
|
|
Margination
|
Accumulation of leukocytes along vascular walls
|
|
Function of selectins
|
tethering of neutrophils and T cells to the endothelial wall
|
|
Function of VCAM 1
|
adhesion of lymphocytes, monocytes, eosinophils, and basophils
|
|
What does E-selectin bind to?
|
Glycoprotein on leukocyte
|
|
What does L-selectin bind to?
|
CD-34 on endothelium
|
|
What does VCAM-1 bind to?
|
Leukocyte VLA-4
|
|
What does ICAM-1 bind to?
|
LFA-1 on T cells
|
|
Function of ICAM?
|
anchors leukocytes to the endothelial cells
|
|
Function of PECAM?
|
transmigration of leukocytes between endothelial cells in vasculature
|
|
What plays a crucial role in activating macrophage effector functions?
|
IFN gamma
|
|
Diseases mediated by DTH reactions
|
- idiopathic uveitis
- inflammatory bowel disease - insulin dependent diabetes - acute cellular graft rejection |
|
Ocular conditions mediated by DTH reactions
|
- corneal graft rejection
- cosmetic-induced conjunctivitis - Behcet's disease - sarcoidosis - sympathetic ophthalmia |
|
Two mechanisms by which extracellular bacteria cause disease:
|
1. Induce inflammation
2. Produce toxins |
|
Endotoxins
|
In bacterial cell wall
Stimulate the production of cytokines by macrophages and other cells (vascular endothelial cells) |
|
Exotoxins
|
Actively secreted by bacteria
(cholera, tetanus, diphtheria) |
|
Antibody isotypes involved in the immune response to extracellular bacteria
|
IgM and IgG
|
|
Mechanisms by which extracellular bacteria evade immunity (2)
|
1. Secretion of substances which inhibit chemotaxis or complement proteins
2. Capsules which interfere with phagocyte binding and complement activation |
|
Major mechanisms of innate immunity to extracellular bacteria (2)
|
1. Phagocytosis by neutrophils, monocytes, and macrophages.
2. Activation of complement |
|
How do viruses enter the host cell?
|
By binding to cell surface molecules (rhinovirus - ICAM; HIV - CD 4, rabies - acetylcholine receptor)
|
|
Cytopathic
|
Interferes with normal cellular protein synthesis
Infected cell dies |
|
Non-cytopathic
|
Proteins from virus become incorporated into MHC molecules on the cell surface and stimulate cytotoxic T cell activity
|
|
Mechanisms of innate immunity in viruses (2)
|
1. IFN released by infected cells
2. Lysis of infected cells by NK cells |
|
Principle mechanism for eliminating viral organisms
|
Cell mediated immunity (action of cytotoxic T lymphocytes)
Recognize viral antigens in association with class I MHC antigens on the surface of any type of cell |
|
Mechanisms by which viruses evade host immunity (2)
|
1. Change their appearance on a molecular level
2. Suppress immune response - attack immune cells & secrete immunosuppressive factors |
|
Toll-like Receptors
|
Bind to different types of microbial molecules (flagellin, glycolipids, RNA, proteins, etc.), which stimulates cells to release cytokines
|
|
Antibody isotype that responds to helminthic parasites
|
IgE
|
|
Main destructor cell in parasitic infection
|
Eosinophil
|
|
Allogenic graft (allograft)
|
a graft transplanted between two genetically different individuals of the same species
|
|
Xenograft
|
a graft transplanted between a host and recipient of two different species
|
|
Which grafts are not rejected?
|
Autografts and isografts
|
|
Which grafts are rejected?
|
Allografts and Xenografts
|
|
Immune response to allogenic antigen
(Direct Pathway) |
T cells, by way of their TCR's, crosss-react and directly bind to foreign MHC molecules on the surface of donor APC's, inducing their activation
|
|
Immune response to allogenic antigen
(Indirect Pathway) |
An allogenic peptide derived from the donor is processed by recipient APCs and is presented to recipient T cells
|
|
Mixed Lymphocyte Reaction (MLR)
|
blood leukocytes from the recipient and donor are co-cultured. Donor cells are treated with anti-miotics.
Difference in the MHC alleles between the donor and recipient will cause the recipient's leukocytes to become activated and will proliferate. This response is measured by the amount of H-thymidine in the DNA of the replicating cells |
|
Function of CD4+ in an allogenic rejection
|
secrete cytokines which helps propagate the MLR response
|
|
Function of CD8+ in allogenic rejection
|
lyse allogenic cells
|
|
Hyperacute Rejection
|
Alloantibodies bind to ABO blood group antigens on endothelial cells and activate complement, which releases thrombotic factors, causing vascular occlusion
Starves everything downstream of the thrombosis = kills the graft |
|
Acute Vascular Rejection
|
alloantibodies bind to other antigens, such as MHC antigens, on endothelial cells and activate complement, causing immediate lysis of the cells.
CD8+ T cells also directly lyse non-MHC indentical donor endothelial cells |
|
Acute Cellular Rejection
|
Parenchymal cells in the graft activate CD4+ cells which initiate a delayed type hypersensitivity reaction against non-MHC identical graft.
Direct lysis of parenchymal cells by CD8+ also occurs. |
|
Two approaches to delay or avoid rejection:
|
1. Make the graft less immunogenic
- Match tissue and blood types - Remove donor lymphocytes (passenger lymphocytes) 2. Suppress the recipient's immune system (cyclosporin) |
|
Graft versus host disease (GVH)
|
allogenic donor lymphocytes react against host tissues in an immunologically compromised host
characterized by lymphocytic infiltration of the skin, liver, and GI tract |
|
How do cyclosporin and tacrolimus work?
|
Inhibits T cell activation by blocking IL-2 production
|
|
How does rapamycin work?
|
Blocks T cell proliferation by inhibiting IL-2 cell signaling
|
|
Carcinomas
|
cancers derived from epithelial cells
|
|
Sarcomas
|
tumors arising from bone, cartilage, and fat
|
|
Lymphomas
|
tumors of the lymphoid tissue
|
|
Leukemias
|
marrow and blood-borne malignant tumors of lymphocytes and other hematopoietic cells
|
|
Teratoma
|
a tumor derived from a mixture of tissues
|
|
Adenomas
|
benign epithelial tumors
|
|
Oncofetal antigens
|
normally expressed in high levels on fetal tissue and low levels on adult tissue
do not cause an immune response measuring levels of these antigens is useful in diagnosis |
|
Which protein is elevated in hepatocellular carcinoma?
|
alpha-feto protein (AFP)
|
|
Which protein is elevated in colon cancer?
|
carcinoembryonic antigen (CEA)
|
|
Which immune cells are not immunologically restricted?
|
NK cells
|
|
Which cytokine mediates the direct and indirect killing of tumor cells by macrophages?
|
TNF
|
|
Antigenic modulation
|
the loss of surface expression of tumor antigens as a result of the internalization of the antigen-antibody complex
|
|
Immunosuppressive factor secreted by some tumors
How does it work? |
TGF-beta
inhibits T and B cell function |
|
More people die from this type of cancer than any other type
|
Lung cancer
|
|
p53 gene function
|
Tumor suppressive gene
Binds to DNA to initiate its repair Mutated p53 can lead to cancer |
|
Adenomatous Polyposis Coli (APC)
|
Tumor suppressive gene
Mutations can cause colon cancer |
|
BRCA-1 and BRCA-2
|
Tumor suppressive genes
Mutations cause breast cancer |
|
Tamoxifen
|
Estrogen receptor blocker
Prevents breast cancer recurrence |
|
Conditions encoded by oncogenic viruses
|
- Epstein-Barr virus
- Human papilloma virus - Human herpes simplex virus 8 - Hepatitis B virus - Human T lymphotropic virus (RNA virus) |
|
FasL
|
mechanism by which tumors evade immune system
tumors express FasL which binds to Fas on T cells, resulting in T cell apoptosis |
|
High doses of this prevents the proliferation of tumor cells
|
IL-2
|
|
Poly ADP Ribose Polymerase (PARP)
|
possibly used in the treatment of ovarian and breast cancer
enzyme involved in reparing single strand DNA breaks in BRCA mutations blocking this enzyme would cause the cancer cell to undergo apoptosis |
|
Mimicry
|
once the body is exposed to a particular antigen, it begins attacking a self cell which expresses an antigen that looks similar to the foreign antigen
|
|
What diseases are caused by mimicry?
|
Thyroiditis and Grave's disease
|
|
What causes myasthenia gravis?
|
a failure to delete self reactive clones. These clones attack self acetyl choline receptors.
|
|
Mechanisms by which autoimmunity develops (4)
|
1. Failure to delete self-reactive clones in the thymus
2. Mimicry 3. Exposure of previously concealed self antigens 4. By pass regulatory mechanisms -- polyclonal activation by LPS |
|
X-linked agammaglobulinemia
|
absence of gamma globulin in the blood
patients with this disease have reduced or entirely missing B cells |
|
DiGeorge Syndrome
|
congenital malformation of the thymus --> defective maturation of T cells
usually normalize by age 5 through the growth of a thymus-like tissue nude (athymic) mouse |
|
Severe combined immunodeficiencies (SCID)
|
defective development of T and B cells
|
|
Transfection
|
gene replacement therapy -- normal gene is linked to the nucleic acid from a non-pathogenic virus which facilitates the gene's entry into the host genome
|
|
Adenosine deaminase
(ADA) |
Enzyme required for the normal metabolism of purines in lymphocytes.
Absence of this enzyme results in accumulation of toxic metabolites which destroy the cell. |
|
A mutation in what gene causes Leber's congenital amaurosis?
|
RPE65
|
|
During HIV infection, what binding causes a conformational change?
|
Binding of gp120 to the CD4 molecule on the cell surface
|
|
What binding allows for the transfer of the HIV viron into the cell?
|
Binding of gp120 to CXCR4
|
|
HIV nef protein
|
mechanism of evading immune detection
downregulates MHC class I molecules from the infected cell's surface --> reduced capacity of the cell to stimulate T cell mediated lysis |
|
Function of Azidothymidine (AZT)
|
reverse transcriptase inhibitor
|
|
Drug that reduces the transmission of HIV from an infected mother to her unborn child
|
Azidothymidine (AZT)
|
|
HAART (highly active anti-retroviral therapy)
|
combination drug of protease inhibitors and reverse transcriptase inhibitors
|
|
Function of protease inhibitors
|
inhibit the proteases required for the packaging of new virions for release from the infected cell
|
|
Side effects of HAART (3)
|
- dyslipidemia
- insulin resistance - premature atherosclerosis |
|
Enfuvirtide
|
prevents HIV from fusing with its target cell by blocking gp41
|
|
Selzentry
|
prevents HIV from fusing with its target cell by blocking the chemokine receptor
|
|
Isentress
|
blocks HIV from integrating into the host genome
|
|
What is the most commonly observed ocular abnormality in AIDS patients?
|
Cotton wool spots
|
|
In 1995, the discovery of which class of drug significantly decreased the death toll of HIV patients?
|
Protease Inhibitors
|
|
Immunological effects of TGF-beta in the eye
|
Inhibits T, B, and NK cell activity
Inhibits the development of cytotoxic T cell and cytokine production |
|
ACAID
|
Suppresses DTH and complement-fixing antibodies
|
|
Where does ocular melanoma tend to metastasize to?
|
The liver
|
|
Leukocoria
|
loss of red reflex
happens in retinoblastoma |
|
What layer of the tears is IgA localized to?
|
Mucin layer
|
|
Lactoferrin
1. Produced by? 2. Function? |
1. Produced by acinar cells
2. Binds iron, which is required for bacterial growth |
|
Lysozyme
1. Function? |
cleaves the cell wall of gram positive bacteria
|
|
Function of Beta lysin
|
disrupts bacterial cell wall and inhibits catalase and peroxidase
|